Secreted frizzled related protein 3 in chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)

Erik Tandberg Askevold, Lars Gullestad, Ståle Nymo, John Kjekshus, Arne Yndestad, Roberto Latini, John G F Cleland, John J V McMurray, Pål Aukrust, Thor Ueland

Research output: Contribution to journalArticle

Abstract

Background We have previously demonstrated an association between increased sFRP3 expression and adverse outcome in a population of HF irrespective of cause and left ventricular ejection fraction. In this study we evaluated the prognostic value of sFRP3 in older patients with chronic systolic HF of ischemic origin. Methods We evaluated sFRP3, by tertiles, as a risk factor for the primary endpoint (cardiovascular [CV] mortality, nonfatal myocardial infarction, nonfatal stroke), all-cause mortality, CV mortality, death from worsening HF (WHF), any coronary event, including sudden death, as well as hospitalizations for CV causes and WHF in 1444 patients from the CORONA population, randomly assigned to 10 mg rosuvastatin or placebo. Results Kaplan-Meier curves for the primary endpoint, as well as all-cause- and CV mortality revealed a markedly better survival for patients with sFRP3 levels in the middle tertile of compared to the 1st and 3rd tertile. In multivariable Cox-regression, after full adjustment including high-sensitive CRP and NT-proBNP, a lower event rate for the primary end point, all cause and CV mortality was observed for patients with tertile 2 sFRP3 levels (HR 0.57 [0.44-0.74], 0.55 [0.44-0.74] and 0.52 [0.39-0.69]; p

Original languageEnglish
Article numbere0133970
JournalPLoS One
Volume10
Issue number8
DOIs
Publication statusPublished - Aug 19 2015

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Secreted frizzled related protein 3 in chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)'. Together they form a unique fingerprint.

  • Cite this

    Askevold, E. T., Gullestad, L., Nymo, S., Kjekshus, J., Yndestad, A., Latini, R., Cleland, J. G. F., McMurray, J. J. V., Aukrust, P., & Ueland, T. (2015). Secreted frizzled related protein 3 in chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). PLoS One, 10(8), [e0133970]. https://doi.org/10.1371/journal.pone.0133970